A Phase 1b study of inhaled RCT1100 in Adults with Primary Ciliary Dyskinesia Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance

2023-510521-14-00 Protocol RCT1100-103 Human pharmacology (Phase I) - Other Ended

Start 18 Oct 2024 · End 8 Jan 2026 · Status Ended · 2 EU/EEA countries · 2 sites · Protocol RCT1100-103

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 15
Countries 2
Sites 2

Adults with Primary Ciliary Dyskinesia

Key facts

Sponsor
Recode Therapeutics Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08]
Trial duration
18 Oct 2024 → 8 Jan 2026
Decision date (initial)
2024-05-28
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Adults with Primary Ciliary Dyskinesia

VersionLevelCodeTermSystem organ class
20.0 PT 10069713 Primary ciliary dyskinesia 100000004850

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Recode Therapeutics Inc.

Sponsor organisation
Recode Therapeutics Inc.
Address
1455 Adams Drive Suite 1120
City
Menlo Park
Postcode
94025-1438
Country
United States

Scientific contact point

Organisation
Recode Therapeutics Inc.
Contact name
Clinical Development

Public contact point

Organisation
Recode Therapeutics Inc.
Contact name
Clinical Development

Locations

2 EU/EEA countries · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Denmark Ended 6 1
Germany Ended 6 1
Rest of world
United States
3

Investigational sites

Denmark

1 site · Ended
Rigshospitalet
Pediatric Pulmonary Service, Blegdamsvej 9, 2100, Copenhagen Oe

Germany

1 site · Ended
Universitaetsklinikum Muenster AöR
General Paediatrics, Albert-Schweitzer-Campus 1, Sentrup, Muenster

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Denmark 2024-10-18 2025-07-09 2024-10-22 2025-04-07
Germany 2024-11-08 2025-09-19 2024-12-02 2025-04-07

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-13 Denmark Acceptable
2024-05-28
2024-05-28
2 SUBSTANTIAL MODIFICATION SM-1 2024-08-22 Denmark Acceptable
2024-09-30
2024-09-30
3 SUBSTANTIAL MODIFICATION SM-3 2024-11-13 Denmark Acceptable
2025-01-17
2025-01-21
4 SUBSTANTIAL MODIFICATION SM-4 2025-03-19 Denmark Acceptable
2025-05-15
2025-05-15
5 SUBSTANTIAL MODIFICATION SM-6 2025-09-19 Acceptable
2025-10-02
2025-10-07